Table 2 Treatment details
From: Latent class analysis of 216 patients with adult-onset Still’s disease
Treatment at disease onset (n=216) | Treatment after first relapse (n=76) | |
|---|---|---|
Corticosteroid, n (%) | 213 (98.6%) | 76 (100%) |
Initial dose of corticosteroid, median mg/day | 40 | 40 |
Pulse corticosteroid therapy, n (%) | 41 (5.3%) | 6 (7.9%) |
Increased corticosteroid, n (%) | N/A | 58 (76.3%) |
Immunosuppressive agents, n (%) | 96 (44.4%) | 38 (50.0%) |
Cyclosporine | 76 (35.2%) | 23 (30.3%) |
Methotrexate | 14 (6.5%) | 6 (7.9%) |
Tacrolimus | 5 (2.3%) | 5 (6.6%) |
Biological agents, n (%) | 22 (10.2%) | 13 (17.1%) |
Tocilizumab | 22 (10.2%) | 11 (14.5%) |
Adalimumab | 0 | 1 (1.3%) |
Etanercept | 0 | 1 (1.3%) |
Plasma exchange, n (%) | 5 (2.3%%) | 0 |